statins and PD
- From: "eml" <mmlevy46@xxxxxxxxxxx>
- Date: 16 Jan 2007 15:11:25 -0800
study by abraham lieberman was discussed on this forum last yr : 2005
Mar;11(2):81-4.
Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease.
Lieberman A, Lyons K, Levine J, Myerburg R.
In which ~600 patients were part of the study, divided into groups
depending upon level of disease progression and then divided into 2
further groups as to whether or not they were taking a statin. though
the conclusion by the author was that there "SEEMED" to be no major
statistical differences in the 2 groups,
(the study has a few problems from my analysis) the most IMPORTANT part
(my opinion)in this study was the notation that 5 patients who were
originally in the non-statin group were started on a statin during the
trial.
ALL FIVE OF THE SUBJECTS DEVELOPED WORSENING OF THEIR SYMPTOMS AFTER
STARTING THE STATIN.
the statins were stopped for a "washing out" period--and after 2 weeks
when the symptoms did not revert to pre-statin levels the investigators
decided that these effects were not caused by the statin and the drugs
were reordered......(the plasma half life of statins is known--the
tissue half life of statins is NOT known--maybe months are required for
statins to be "washed out" of tissues)
statins do more than just decrease LDL (which is not a fat, but a lipid
and a protein that act as carriers for cholesterol and triglycerides)
statins interrupt isoprentylation of many substances one of which
results in a depression in selenoprotein expression. the functions of
selenium(selenium has myriad metabolic functions-- are carried out by
selenoproteins. several selenoproteins are expressed in the brain.
glutathione peroxidase is one of these, serving an important role as
protection from reactive oxygen species-induced cell damage. selenium
concentrations in the CSF and serum of patients with PD are lower
compared to normal subjects. [meseguer et al 1999, aguilar et al
1998])and the lowest density of glutathione peroxidase positive glial
cells is found in the substantia nigra--leaving this dopaminergic cell
group with less protection from oxidative stress and vulnerable to PD
(Damier et al 1996) (there is a doc in Fla, Pearlman, who will give IV
glutathione to PD patients and there is currently a study at the univ
of fla (or one of the med schools in fla) looking at the use of IV
glutathione in PD--please understand i am not endorsing the use of IV
glutathione for PD-from my understanding, it should result in initial
symptom improvements, but very soon loses effectiveness; i hope i am
incorrect)
and of course statins interrupt the pathway to coenzyme q10 production.
that has been discussed on this forum many times--and the importance of
coq10 to the mitochondrial electron transport chain--esp complexes 1, 2
and 4 (there is a well regarded theory that parkinson's is the result
of mitochondrial dysfunction, specifically dysfunction of complex 1 of
the ETC) and for coq10's function as a major anti-oxidant , esp in the
brain....
.
- Prev by Date: cholesterol-making or breaking the synapse
- Next by Date: Re: Echo results and a strange question... need some opinions...
- Previous by thread: cholesterol-making or breaking the synapse
- Next by thread: Re: Folic acid and homocysteine--a meta-analysis
- Index(es):
Relevant Pages
|
Loading
